Regulation of Toll-like receptor signaling in the innate immunity

Science China Life Sciences

Volumn 53, Issue 1, 2010, Pages 34-43

  An, HuaZhang ^a   Qian, Cheng ^a   Cao, XueTao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

TLR signaling; Toll like receptors

Indexed keywords

CYTOKINE; INTERFERON; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ANIMAL; BIOLOGICAL MODEL; HUMAN; INNATE IMMUNITY; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 76649084547     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-0011-x     Document Type: Review

References (95)

1. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 1996, 86: 973-983.
2. Medzhitov R, Preston-Hurlburt P, Janeway C A, et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997, 388: 394-397.
3. Akira S. Toll-like receptor signaling. J Biol Chem, 2003, 278: 38105-38108.
4. Schnare M, Barton G M, Holt A C, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol, 2001, 2: 947-950.
5. Liew F Y, Xu D, Brint E K, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol, 2005, 5: 446-458.
6. Ozinsky A, Underhill D M, Fontenot J D, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA, 2000, 97: 13766-13771.
7. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002, 169: 10-14.
8. Omueti K O, Beyer J M, Johnson C M, et al. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem, 2005, 280: 36616-36625.
9. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science, 2008, 320: 379-381.
10. Park B S, Song D H, Kim H M, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009, 458: 1191-1195.
11. O'Neill L A, Bowie A G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol, 2007, 7: 353-364.
12. LeBouder E, Rey-Nores J E, Rushmere N K, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol, 2003, 171: 6680-6689.
13. Iwami K I, Matsuguchi T, Masuda A, et al. Cutting edge: Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol, 2000, 165: 6682-6686.
14. Kagan JC, Su T, Horng T, et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol, 2008, 9: 361-368.
15. Cao X. Forefront of progress in immunology. Beijing: People's Medical Publishing House, 2009. 136-160.
16. Lord K A, Hoffman-Liebermann B, Liebermann D A. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene, 1990, 5: 1095-1097.
17. Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278: 1612-1615.
18. Wesche H, Henzel W J, Shillinglaw W, et al. MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity, 1997, 7: 837-847.
19. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 1999, 11: 115-122.
20. Janssens S, Burns K, Tschopp J, et al. Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol, 2002, 12: 467-471.
21. Burns K, Janssens S, Brissoni B, et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med, 2003, 197: 263-268.
22. Fitzgerald K A, Palsson-McDermott E M, Bowie A G, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature, 2001, 413: 78-83.
23. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature, 2002, 420: 324-329.
24. Horng T, Barton G M, Flavell R A, et al. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature, 2002, 420: 329-333.
25. Kagan J C, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell, 2006, 125: 943-955.
26. Ohnishi H, Tochio H, Kato Z, et al. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA, 2009, 106: 10260-10265.
27. Kanakaraj P, Schafer P H, Cavender D E, et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med, 1998, 187: 2073-2079.
28. Thomas J A, Allen J L, Tsen M, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol, 1999, 163: 978-984.
29. Li S, Strelow A, Fontana E J, et al. IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA, 2002, 99: 5567-5572.
30. Kobayashi K, Hernandez L D, Galan J E, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell, 2002, 110: 191-202.
31. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science, 2003, 299: 2076-2079.
32. Kim T W, Staschke K, Bulek K, et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med, 2007, 204: 1025-1036.
33. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol, 2008, 9: 684-691.
34. Ye H, Arron J R, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature, 2002, 418: 443-447.
35. Jacinto R, Hartung T, McCall C, et al. Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: Distinct alterations in IL-1 receptor-associated kinase. J Immunol, 2002, 168: 6136-6141.
36. Li X, Commane M, Burns C, et al. Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol, 1999, 19: 4643-4652.
37. Jensen L E, Whitehead A S. IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability. J Biol Chem, 2001, 276: 29037-29044.
38. Rao N, Nguyen S, Ngo K, et al. A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol Cell Biol, 2005, 25: 6521-6532.
39. Hardy M P, O'Neill L A. The murine IRAK2 gene encodes four alternatively spliced isoforms, two of which are inhibitory. J Biol Chem, 2004, 279: 27699-27708.
40. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature, 2001, 412: 346-351.
41. Kawai T, Sato S, Ishii K J, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol, 2004, 5: 1061-1068.
42. Hacker H, Redecke V, Blagoev B, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 2006, 439: 204-207.
43. Oganesyan G, Saha S K, Guo B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature, 2006, 439: 208-211.
44. Zarnegar B J, Wang Y, Mahoney D J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol, 2008, 9: 1371-1378.
45. Zarnegar B, Yamazaki S, He J Q, et al. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA, 2008, 105: 3503-3508.
46. Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol, 2005, 6: 1087-1095.
47. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell, 2000, 5: 649-658.
48. Xia Z P, Sun L, Chen X, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature, 2009, 7620: 114-119.
49. Liu X, Yao M, Li N, et al. CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood, 2008, 112: 4961-4970.
50. Yamamoto M, Sato S, Mori K, et al. Cutting edge: A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol, 2002, 169: 6668-6672.
51. Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature, 2003, 424: 743-748.
52. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 2003, 301: 640-643.
53. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol, 2003, 4: 161-167.
54. Sato S, Sugiyama M, Yamamoto M, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol, 2003, 171: 4304-4310.
55. Jiang Z, Mak T W, Sen G, et al. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA, 2004, 101: 3533-3538.
56. An H, Hou J, Zhou J, et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol, 2008, 9: 542-550.
57. Wietek C, Miggin S M, Jefferies C A, et al. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa. J Biol Chem, 2003, 278: 50923-50931.
58. Palsson-McDermott E M, Doyle S L, McGettrick A F, et al. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat Immunol, 2009, 10: 579-586.
59. Brint E K, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol, 2004, 5: 373-379.
60. Sweet M J, Leung B P, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol, 2001, 166: 6633-6639.
61. Wald D, Qin J, Zhao Z, et al. SIGIR R, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol, 2003, 4: 920-927.
62. Divanovic S, Trompette A, Atabani S F, et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol, 2005, 6: 571-578.
63. Diehl G E, Yue H H, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity, 2004, 21: 877-889.
64. Rui Y, Liu X, Li N, et al. PECAM-1 ligation negatively regulates TLR4 signaling in macrophages. J Immunol, 2007, 179: 7344-7351.
65. Hamerman J A, Tchao N K, Lowell C A, et al. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol, 2005, 6: 579-586.
66. Turnbull I R, McDunn J E, Takai T, et al. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J Exp Med, 2005, 202: 363-369.
67. Carty M, Goodbody R, Schroder M, et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol, 2006, 7: 1074-1081.
68. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol, 2000, 2: 346-351.
69. Bulut Y, Faure E, Thomas L, et al. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: Role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol, 2001, 167: 987-994.
70. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem, 2002, 277: 7059-7065.
71. Wang Y, Tang Y, Teng L, et al. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol, 2006, 7: 139-147.
72. Kawagoe T, Takeuchi O, Takabatake Y, et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol, 2009, 10: 965-972.
73. Zhao Q, Wang X, Nelin L D, et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med, 2006, 203: 131-140.
74. Hammer M, Mages J, Dietrich H, et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med, 2006, 203: 15-20.
75. Chi H, Barry S P, Roth R J, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA, 2006, 103: 2274-2279.
76. Jeffrey K L, Brummer T, Rolph M S, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol, 2006, 7: 274-283.
77. Xu H, An H, Hou J, et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol Immunol, 2008, 45: 3545-3552.
78. An H, Zhao W, Hou J, et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity, 2006, 25: 919-928.
79. Chuang T H, Ulevitch R J. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol, 2004, 5: 495-502.
80. Wang Y, Chen T, Han C, et al. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood, 2007, 110: 962-971.
81. Yao M, Liu X, Li D, et al. Late endosome/lysosome-localized Rab7b suppresses TLR9-initiated proinflammatory cytokine and type I IFN production in macrophages. J Immunol, 2009, 183: 1751-1758.
82. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002, 17: 583-591.
83. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity, 2002, 17: 677-687.
84. Mansell A, Smith R, Doyle S L, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol, 2006, 7: 148-155.
85. Gingras S, Parganas E, de Pauw A, et al. Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem, 2004, 279: 54702-54707.
86. Baetz A, Frey M, Heeg K, et al. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem, 2004, 279: 54708-54715.
87. Boone D L, Turer E E, Lee E G, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 2004, 5: 1052-1060.
88. Saitoh T, Yamamoto M, Miyagishi M, et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol, 2005, 174: 1507-1512.
89. Bignell G R, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet, 2000, 25: 160-165.
90. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature, 2003, 424: 801-805.
91. Brummelkamp T R, Nijman S M, Dirac A M, et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature, 2003, 424: 797-801.
92. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature, 2003, 424: 793-796.
93. Yoshida H, Jono H, Kai H, et al. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem, 2005, 280: 41111-41121.
94. Wang C, Chen T, Zhang J, et al. The E3 ubiquitin ligase Nrdp1' preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol 2009, 10: 744-752.
95. Shi M, Deng W, Bi E, et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol, 2008, 9: 369-377.